Log in

NASDAQ:HOLXHologic Stock Price, Forecast & News

$57.86
0.00 (0.00 %)
(As of 07/6/2020 04:00 PM ET)
Add
Compare
Today's Range
$57.63
Now: $57.86▼
$59.14
50-Day Range
$50.15
MA: $53.40▼
$57.86
52-Week Range
$26.49
Now: $57.86▼
$59.14
Volume2.47 million shs
Average Volume2.79 million shs
Market Capitalization$14.94 billion
P/E Ratio25.27
Dividend YieldN/A
Beta1.47
Hologic, Inc., a medical technology company, develops, manufactures, and supplies diagnostics products, medical imaging systems, and surgical products for women in the United States, Europe, the Asia-Pacific, and internationally. It operates in five segments: Diagnostics, Breast Health, Medical Aesthetics, GYN Surgical, and Skeletal Health. The company offers Aptima molecular diagnostic assays, target capture/nucleic acid extraction technology, transcription-mediated amplification technology, hybridization protection and dual kinetic assay technologies, instrumentation, Invader chemistry platform, ThinPrep system, and rapid fetal fibronectin test products. It also provides breast imaging and analytics products, such as 2D and 3D mammography systems and reading workstations, minimally invasive breast biopsy guidance systems and devices, and breast biopsy and biopsy site markers, as well as localization, specimen radiology, ultrasound, and connectivity solutions. In addition, the company offers Selenia Dimensions and 3Dimensions gantries for performing 2D and tomosynthesis image acquisition and display; C-View and Intelligent 2D software products; SecurView Workstations; computer aided detection systems; and stereotactic breast biopsy systems. Further, it provides SculpSure, PicoSure, and MonaLisa Touch aesthetic treatment systems; TempSure, a radio frequency energy sourced platform; and MedLite and other products, and system components for medical aesthetics. Additionally, the company offers NovaSure, an endometrial ablation system to treat women suffering from abnormal uterine bleeding; MyoSure surgical products for removal of fibroids, and uterine polyps and other pathology; and Horizon DXA System and Fluoroscan Insight FD skeletal health products. It sells its products through direct sales and service forces, and a network of independent distributors and sales representatives. The company was founded in 1985 and is headquartered in Marlborough, Massachusetts.
Read More
Hologic logo

Beat the Market (BTM) Rank™

Analyst Opinion: 2.4Community Rank: 2.8Dividend Strength: 0.0Insider Behavior: 1.0Valuation: 1.9 5 -4 -3 -2 -1 -

Overall Beat the Market Rank™

1.61 out of 5 stars


Industry, Sector and Symbol

Stock Exchange NASDAQ
Industry X-ray apparatus & tubes
Sub-IndustryHealth Care Equipment
SectorMedical
Current SymbolNASDAQ:HOLX
Previous Symbol
CUSIP43644010
CIK859737
Webwww.hologic.com
Phone508-263-2900

Debt

Debt-to-Equity Ratio1.32
Current Ratio1.31
Quick Ratio1.04

Price-To-Earnings

Trailing P/E Ratio25.27
Forward P/E Ratio25.38
P/E Growth3.61

Sales & Book Value

Annual Sales$3.37 billion
Price / Sales4.44
Cash Flow$4.20 per share
Price / Cash Flow13.78
Book Value$7.91 per share
Price / Book7.31

Profitability

EPS (Most Recent Fiscal Year)$2.43
Net Income$-203,600,000.00
Net Margins18.53%
Return on Equity30.49%
Return on Assets10.14%

Miscellaneous

Employees6,478
Outstanding Shares258,206,000
Market Cap$14.94 billion
Next Earnings Date7/29/2020 (Confirmed)
OptionableOptionable
NASDAQ:HOLX Rates by TradingView

Receive HOLX News and Ratings via Email

Sign-up to receive the latest news and ratings for HOLX and its competitors with MarketBeat's FREE daily newsletter.

Hologic (NASDAQ:HOLX) Frequently Asked Questions

How has Hologic's stock been impacted by COVID-19 (Coronavirus)?

Hologic's stock was trading at $43.78 on March 11th, 2020 when Coronavirus reached pandemic status according to the World Health Organization (WHO). Since then, HOLX shares have increased by 32.2% and is now trading at $57.86. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Hologic?

17 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Hologic in the last year. There are currently 5 hold ratings and 12 buy ratings for the stock, resulting in a consensus recommendation of "Buy." View analyst ratings for Hologic.

When is Hologic's next earnings date?

Hologic is scheduled to release its next quarterly earnings announcement on Wednesday, July 29th 2020. View our earnings forecast for Hologic.

How can I listen to Hologic's earnings call?

Hologic will be holding an earnings conference call on Wednesday, July 29th at 12:00 AM Eastern. Interested parties can register for or listen to the call using this link or dial in at Not Available.

How were Hologic's earnings last quarter?

Hologic, Inc. (NASDAQ:HOLX) issued its quarterly earnings results on Wednesday, April, 29th. The medical equipment provider reported $0.57 EPS for the quarter, meeting the Zacks' consensus estimate of $0.57. The medical equipment provider had revenue of $756.10 million for the quarter, compared to the consensus estimate of $756.10 million. Hologic had a net margin of 18.53% and a return on equity of 30.49%. During the same quarter in the prior year, the company posted $0.58 earnings per share. View Hologic's earnings history.

What price target have analysts set for HOLX?

17 brokers have issued 12 month target prices for Hologic's shares. Their forecasts range from $43.00 to $64.00. On average, they expect Hologic's share price to reach $57.35 in the next twelve months. This suggests that the stock has a possible downside of 0.9%. View analysts' price targets for Hologic.

What are Wall Street analysts saying about Hologic stock?

Here are some recent quotes from research analysts about Hologic stock:
  • 1. According to Zacks Investment Research, "In recent times, Hologic registered strong top-line growth led by robust performances within majority of its businesses. In the last reported quarter, organic revenue growth against the toughest comparable of the year, significantly outdid Hologic’s projections. Continued solid uptake of Aptima women's health assays and consistent expansion of global installed bases of Genius 3D mammography systems and Panther instruments are encouraging. It put up a robust first quarter fiscal 2020 show with in-line earnings and revenues ahead of expectations. However, the contractions in both margins during the quarter are concerning. Difficult macroeconomic conditions due to coronavirus outbreak and foreign exchange fluctuations are other headwinds trailing the company. Overall, Hologic has been underperforming its industry over the past three months." (4/28/2020)
  • 2. Canaccord Genuity analysts commented, "We look for greater evidence for Hologic to find a solution to its declining gross margins and we need more time to get confident that Cynosure has bottomed. Nevertheless, near mid-single-digit growth and effective capital allocation (buybacks and tuck-in deals) are warming us up to the stock as HOLX delivered a 2% top-line beat, 2 cent bottom-line beat, and raised its FY top- and bottom-line guide. That said, its FY’19 raised" revenue is less than the FQ3 $17M beat (FX headwinds being one factor), a consistent trend of setting a low bar for the next reporting quarter and essentially not raising its underlying baseline guide. We reiterate our HOLD, PT to $52. FQ3 beat. (+3.4% rep, +4.7% FXN) exceeded our/Street’s $835ME and adj." (8/1/2019)
  • 3. Needham & Company LLC analysts commented, "FDA’s latest monthly Act (MQSA) statistics were published on 7/1/19. The number of digital breast tomosynthesis (DBT) units increased by 92 during June which represents a 30.8% Y/Y decrease. DBT unit penetration increased to 37.3% from 37.0% last month and facility penetration increased to 62.1% from 61.4% last month. More importantly, DBT units placements were up 2.7% quarter-to-date (QTD) in 2Q19 vs. 2Q18. We note that HOLX’s 3D mammography sales are less than 13% of its total sales. Please contact your Needham salesperson for a copy of our MQSA spreadsheet." (7/10/2019)

Has Hologic been receiving favorable news coverage?

News headlines about HOLX stock have trended negative recently, InfoTrie Sentiment reports. The research group scores the sentiment of media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of public companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Hologic earned a media sentiment score of -2.1 on InfoTrie's scale. They also assigned news stories about the medical equipment provider a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an impact on the stock's share price in the near future. View the latest news about Hologic.

Are investors shorting Hologic?

Hologic saw a increase in short interest in June. As of June 30th, there was short interest totaling 4,130,000 shares, an increase of 20.1% from the June 15th total of 3,440,000 shares. Based on an average daily trading volume, of 2,990,000 shares, the short-interest ratio is presently 1.4 days. Approximately 1.6% of the company's stock are short sold. View Hologic's Current Options Chain.

Who are some of Hologic's key competitors?

What other stocks do shareholders of Hologic own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Hologic investors own include AbbVie (ABBV), Starbucks (SBUX), Walt Disney (DIS), Johnson & Johnson (JNJ), Alibaba Group (BABA), Bank of America (BAC), NVIDIA (NVDA), salesforce.com (CRM), Medtronic (MDT) and Paypal (PYPL).

Who are Hologic's key executives?

Hologic's management team includes the following people:
  • Mr. Stephen P. MacMillan, Chairman, CEO & Pres (Age 55)
  • Ms. Karleen M. Oberton, Chief Financial Officer (Age 49)
  • Mr. John M. Griffin, Gen. Counsel (Age 58)
  • Mr. Peter J. Valenti III, Division Pres of Breast & Skeletal Health Solutions (Age 56)
  • Mr. Thomas A. West, Division Pres of Diagnostics Solutions (Age 55)

What is Hologic's stock symbol?

Hologic trades on the NASDAQ under the ticker symbol "HOLX."

Who are Hologic's major shareholders?

Hologic's stock is owned by a variety of retail and institutional investors. Top institutional investors include State of Alaska Department of Revenue (0.05%) and Ellevest Inc. (0.00%). Company insiders that own Hologic stock include Allison P Bebo, Benjamin Jordan Cohn, Christiana Stamoulis, John M Griffin, Karleen Marie Oberton, Peter J Valenti III, Sally Crawford and Stephen P Macmillan. View institutional ownership trends for Hologic.

Which major investors are selling Hologic stock?

HOLX stock was sold by a variety of institutional investors in the last quarter, including State of Alaska Department of Revenue, and Ellevest Inc.. Company insiders that have sold Hologic company stock in the last year include Benjamin Jordan Cohn, Christiana Stamoulis, John M Griffin, Karleen Marie Oberton, Peter J Valenti III, Sally Crawford, and Stephen P Macmillan. View insider buying and selling activity for Hologic.

How do I buy shares of Hologic?

Shares of HOLX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Hologic's stock price today?

One share of HOLX stock can currently be purchased for approximately $57.86.

How big of a company is Hologic?

Hologic has a market capitalization of $14.94 billion and generates $3.37 billion in revenue each year. The medical equipment provider earns $-203,600,000.00 in net income (profit) each year or $2.43 on an earnings per share basis. Hologic employs 6,478 workers across the globe.

What is Hologic's official website?

The official website for Hologic is www.hologic.com.

How can I contact Hologic?

Hologic's mailing address is 250 CAMPUS DRIVE, MARLBOROUGH MA, 01752. The medical equipment provider can be reached via phone at 508-263-2900 or via email at [email protected]

This page was last updated on 7/7/2020 by MarketBeat.com Staff

30 Days of MarketBeat All Access for $1.00

Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools:

  • Best-in-Class Portfolio Monitoring

    View the latest news, buy/sell ratings, SEC filings and insider transactions for your stocks. Compare your portfolio performance to leading indices and get personalized stock ideas based on your portfolio.

  • Stock Ideas and Recommendations

    Get daily stock ideas top-performing Wall Street analysts. Get short term trading ideas from the MarketBeat Idea Engine. View which stocks are hot on social media with MarketBeat's trending stocks report.

  • Advanced Stock Screeners and Research Tools

    Identify stocks that meet your criteria using seven unique stock screeners. See what's happening in the market right now with MarketBeat's real-time news feed. Export data to Excel for your own analysis.

Start Your Risk-Free Trial Subscription Here
Receive Analysts' Upgrades and Downgrades Daily

Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with MarketBeat.com's FREE daily email newsletter.